Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today. In honor of Rare Disease Day, we sat down with Paul Melmeyer of the National Organization for Rare Disorders (NORD) to discuss rare diseases, how we can spur innovation and what can we do to raise awareness.
Q: Today is Rare Disease Day. What should people know about rare diseases that they might not?
A: Those who are unaware of rare diseases are generally surprised by just how common they really are in the aggregate. A rare disease is defined by the Orphan Drug Act (ODA) as any disease or condition with fewer than 200,000 individuals diagnosed in the U.S., and most qualifying diseases may only affect a few thousand individuals or fewer. Yet added altogether, rare diseases affect more than 30 million Americans – more than almost all other chronic conditions in the U.S. Almost everyone has a family member, friend, co-worker, classmate, or perhaps themselves who has a rare disease. Rare diseases are much more common than one may think.
Q: How has the Orphan Drug Act been helpful to spurring rare disease advances?
A: The ODA has been integral to the growth of the number of orphan therapies available to rare disease patients today. Prior to 1983, there were only 34 therapies that would qualify as an orphan therapy available in the U.S. Today, we have over 770 orphan therapies approved by the U.S. Food and Drug Administration (FDA). Last year, for the first time ever, orphan therapies comprised a majority of novel therapies approved by FDA. Given the unmet need of rare diseases, it is critical the ODA continue to help spur newfound innovations.
Q: What can the health care community do to raise awareness about rare diseases?
A: The health care community can and should raise awareness about rare diseases in various ways. First, we need to counter the old medical school saying, “when you hear hoofbeats, think horses.” It might just be a zebra! This means that when approaching a diagnosis, health professionals should be every bit as mindful of rare diseases as they are of common diseases. Second, health professionals should listen to individuals with rare diseases, their caregivers, and their representatives at patient organizations. They know what is best for them and their community, and often the best that health professionals can do is listen. Finally, we need students at all levels to learn about rare diseases and consider ways in which to serve the community as they launch their careers. This is why NORD is operating a student chapter and student club program to train the next generation of rare disease professionals.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
Mass compounding puts patients at risk
World Sickle Cell Day: Recognizing the promise of gene therapy
Celebrating rare disease innovation: Progress and the path forward
Advancing patient care: A look at new medicines approved in 2025
Knockoffs of FDA-approved drugs put patients at risk
PDUFA: Essential to America’s edge in drug development and patient access
4 things to know on Rare Disease Day
Major drug compounder is spending millions on misleading Super Bowl ad
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
More oversight needed of unapproved medicines that threaten patients’ health
The use of real-world data in drug development
New analysis: Accelerated approval pathway is changing lives in underserved communities
Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
Florida’s importation plan puts patients in danger
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
Don't close the door on rare disease research
Decentralized clinical trials and the future of drug development
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
How FDA’s modernization strategy could improve drug development
Setting the record straight on accelerated approval
FDA should remain the authority on the safety and effectiveness of medicines
Celebrating 40 years of the Orphan Drug Act on Rare Disease Day
What you should know about real-world evidence and drug development
Three things to know about the accelerated approval pathway
PDUFA and BsUFA reauthorizations are wins for patients
Recognizing National Sickle Cell Awareness Month
Word of the Month: Biomarkers and surrogate endpoints
Ensuring timely reauthorization of PDUFA and BsUFA
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
Biopharmaceutical research and development has ushered in a decade of innovation in rare disease
The importance of timely PDUFA and BsUFA reauthorization
ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients
New Report: Nearly 800 new medicines in development to treat rare diseases
3 things to know about the importance of post-approval research and development
Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition
Meeting Tomorrow: Looking ahead to PDUFA VII
The impact of monoclonal antibodies and COVID-19 recovery
PDUFA VII is critical for future biopharmaceutical innovation and for patients
How strengthening the biosimilar marketplace benefits patients
The FDA Office of Minority Health and Health Equity: Working to advance health equity through diversity in research
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
Nearly 400 cell and gene therapies in development to target a broad range of diseases
Rare Disease Day 2020: Progress toward cures
ICYMI: 2019 brings innovative medicines to patients
PhRMA comments to Congress on Cures 2.0 call to action
Speaker Pelosi’s drug pricing plan could result in 56 fewer new medicines over 10 years
Pelosi’s radical plan would leave patients with sickle cell disease behind
Pelosi’s radical plan would leave patients with rare pediatric diseases behind
ICYMI: Fighting for a cure to ALS
Guest Post: Using the patient voice to go boldly
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
New report shows nearly 20 innovative medicines in development for sickle cell disease
Rare Disease Day: Unmet medical need inspires biopharmaceutical innovation
Why state drug importation pilot programs don’t work
Putting 2018 medicine approvals in context
FDA needs best and brightest to advance a new era of medicine with America’s biopharmaceutical companies
Balancing innovation and competition in the biologics marketplace
New analysis shows that more medicines worldwide are available to U.S. patients
ICYMI: Orphan drug development brings unique challenges
Spending on medicines grew less than one percent in 2017
Rare Disease Day: Unmet need inspires innovation
Innovation comes in many forms, including new and expanded uses of existing medicines
ICYMI: Why 2017 medicine approvals matter
New surveys find payers and providers want more data from biopharmaceutical companies
Supporting opportunities for enhanced competition in the marketplace
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Opportunities to build upon enhanced competition for medicines in the marketplace
Why reauthorization of PDUFA matters
A critical opportunity to prevent prescription drug abuse
Guest Post: The importance of a modern FDA in drug discovery
Guest Post: Debra of America on Epidermolysis Bullosa
Guest Post: Room for optimism in ALS research
Guest Post: A Cure for Ellie on Leukodystrophy-LBSL
Guest Post: Epilepsy Foundation on rare diseases
Rare Disease Day: Accelerating innovation for patients in need
Guest post: Hearing from patients on Rare Disease Day
Rare Diseases
FDA
Guest post: Hearing from patients on Rare Disease Day
Guest post: Hearing from patients on Rare Disease Day